JNCE logo

Jounce Therapeutics (JNCE) Free Cash Flow

Annual FCF

-$29.80 M
+$54.07 M+64.47%

December 31, 2022

Summary

Performance

1-Year Change

+64.47%

3-Year Change

+4.24%

5-Year Change

+71.92%

15-Year Change

+71.92%

JNCE Free Cash Flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$177.47 M
JNCE annual free cash flow is currently -116.79% below its historical high of $177.47 million

3-Year Low

-$83.87 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
JNCE previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
JNCE next annual earnings announcement has not yet been scheduled

OtherJNCEcash flowmetrics:

Annual CFO

-$28.88 M
JNCE annual cash flow from operations is -$28.88 million

Annual CFF

$442.00 K
JNCE annual cash flow from financing activities is $442.00 thousand

Annual CFI

$83.48 M
JNCE annual cash flow from investing activities is $83.48 million

Annual CAPEX

$919.00 K
JNCE annual capital expenditures is $919.00 thousand

Quarterly FCF

$59.01 M
+$90.79 M+285.69%

December 31, 2022

Summary

Performance

3-Month Change

+285.69%

1-Year Change

+308.32%

3-Year Change

+417.28%

5-Year Change

+330.65%

JNCE Quarterly FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$214.22 M
JNCE quarterly free cash flow is currently -72.45% below its historical high of $214.22 million

3-Year Low

-$33.27 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2022
JNCE previous earnings announcement was published on Dec 31, 2022

Next Quarterly Earnings Report Date

N/A
JNCE next earnings announcement has not yet been scheduled

OtherJNCEcash flowmetrics:

Quarterly CFO

$59.23 M
JNCE quarterly cash flow from operations is $59.23 million

Quarterly CFF

$0.00
JNCE quarterly cash flow from financing activities is $0.00

Quarterly CFI

$14.23 M
JNCE quarterly cash flow from investing activities is $14.23 million

Quarterly CAPEX

$223.00 K
JNCE quarterly capital expenditures is $223.00 thousand

TTM FCF

-$29.80 M
+$87.34 M+74.56%

December 31, 2022

Summary

Performance

3-Month Change

+74.56%

1-Year Change

+64.47%

3-Year Change

+4.24%

5-Year Change

+4.24%

JNCE TTM FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$190.31 M
JNCE TTM free cash flow is currently -115.66% below its historical high of $190.31 million

3-Year Low

-$117.13 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2022
JNCE previous earnings announcement was published on Dec 31, 2022

Next Quarterly Earnings Report Date

N/A
JNCE next earnings announcement has not yet been scheduled

OtherJNCEcash flowmetrics:

TTM CFO

-$28.88 M
JNCE TTM cash flow from operations is -$28.88 million

TTM CFF

$442.00 K
JNCE TTM cash flow from financing activities is $442.00 thousand

TTM CFI

$83.48 M
JNCE TTM cash flow from investing activities is $83.48 million

TTM CAPEX

$919.00 K
JNCE TTM capital expenditures is $919.00 thousand

Free Cash Flow Formula

FCF = Cash From Operations − CAPEX

Annual FCF

-$29.80 M
JNCE annual free cash flow is -$29.80 million

Annual CFO

-$28.88 M
JNCE annual cash flow from operations is -$28.88 million

Annual CAPEX

$919.00 K
JNCE annual capital expenditures is $919.00 thousand

JNCE Free Cash Flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+64.5%+308.3%+64.5%
3 y3 years+4.2%+417.3%+4.2%
5 y5 years+71.9%+330.6%+4.2%

JNCE Free Cash Flow Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+181.5%at high-156.4%at high+293.1%
5 y5-year+6.9%+181.5%at high-157.1%+83.5%+293.1%
alltimeall time-116.8%+256.1%-72.5%-157.1%-115.7%+293.1%

Jounce Therapeutics Free Cash Flow History

DateAnnualQuarterlyTTM
Dec 2022
-$29.80 M(-64.5%)
$59.01 M(-285.7%)
-$29.80 M(-74.6%)
Sep 2022
-
-$31.78 M(+33.8%)
-$117.13 M(+42.4%)
Jun 2022
-
-$23.75 M(-28.6%)
-$82.27 M(-1.4%)
Mar 2022
-
-$33.27 M(+17.5%)
-$83.43 M(-0.5%)
Dec 2021
-$83.87 M(+200.8%)
-$28.33 M(-1019.4%)
-$83.87 M(+416.5%)
Sep 2021
-
$3.08 M(-112.4%)
-$16.24 M(-60.8%)
Jun 2021
-
-$24.91 M(-26.1%)
-$41.48 M(+9.2%)
Mar 2021
-
-$33.71 M(-185.8%)
-$38.00 M(+36.3%)
Dec 2020
-$27.88 M(-10.4%)
$39.30 M(-277.4%)
-$27.88 M(-67.5%)
Sep 2020
-
-$22.16 M(+3.4%)
-$85.78 M(+175.8%)
Jun 2020
-
-$21.43 M(-9.2%)
-$31.10 M(-1.0%)
Mar 2020
-
-$23.60 M(+26.9%)
-$31.42 M(+1.0%)
Dec 2019
-$31.11 M
-$18.60 M(-157.2%)
-$31.11 M(-3.3%)
Sep 2019
-
$32.52 M(-249.6%)
-$32.19 M(-61.4%)
Jun 2019
-
-$21.75 M(-6.6%)
-$83.37 M(+24.6%)
DateAnnualQuarterlyTTM
Mar 2019
-
-$23.29 M(+18.4%)
-$66.92 M(+3.0%)
Dec 2018
-$64.97 M(-38.8%)
-$19.67 M(+5.4%)
-$64.97 M(-8.3%)
Sep 2018
-
-$18.66 M(+253.0%)
-$70.89 M(-10.0%)
Jun 2018
-
-$5.29 M(-75.2%)
-$78.76 M(-23.5%)
Mar 2018
-
-$21.35 M(-16.6%)
-$102.93 M(-3.0%)
Dec 2017
-$106.09 M(-159.8%)
-$25.59 M(-3.6%)
-$106.09 M(+13.7%)
Sep 2017
-
-$26.54 M(-9.9%)
-$93.35 M(-163.3%)
Jun 2017
-
-$29.45 M(+20.1%)
$147.41 M(-10.5%)
Mar 2017
-
-$24.52 M(+90.9%)
$164.66 M(-7.2%)
Dec 2016
$177.47 M(-735.1%)
-$12.84 M(-106.0%)
$177.47 M(-6.7%)
Sep 2016
-
$214.22 M(-1855.6%)
$190.31 M(-895.9%)
Jun 2016
-
-$12.20 M(+4.2%)
-$23.91 M(+104.2%)
Mar 2016
-
-$11.71 M
-$11.71 M
Dec 2015
-$27.94 M(+79.0%)
-
-
Dec 2014
-$15.61 M
-
-

FAQ

  • What is Jounce Therapeutics annual free cash flow?
  • What is the all time high annual FCF for Jounce Therapeutics?
  • What is Jounce Therapeutics annual FCF year-on-year change?
  • What is Jounce Therapeutics quarterly free cash flow?
  • What is the all time high quarterly FCF for Jounce Therapeutics?
  • What is Jounce Therapeutics quarterly FCF year-on-year change?
  • What is Jounce Therapeutics TTM free cash flow?
  • What is the all time high TTM FCF for Jounce Therapeutics?
  • What is Jounce Therapeutics TTM FCF year-on-year change?

What is Jounce Therapeutics annual free cash flow?

The current annual FCF of JNCE is -$29.80 M

What is the all time high annual FCF for Jounce Therapeutics?

Jounce Therapeutics all-time high annual free cash flow is $177.47 M

What is Jounce Therapeutics annual FCF year-on-year change?

Over the past year, JNCE annual free cash flow has changed by +$54.07 M (+64.47%)

What is Jounce Therapeutics quarterly free cash flow?

The current quarterly FCF of JNCE is $59.01 M

What is the all time high quarterly FCF for Jounce Therapeutics?

Jounce Therapeutics all-time high quarterly free cash flow is $214.22 M

What is Jounce Therapeutics quarterly FCF year-on-year change?

Over the past year, JNCE quarterly free cash flow has changed by +$87.34 M (+308.32%)

What is Jounce Therapeutics TTM free cash flow?

The current TTM FCF of JNCE is -$29.80 M

What is the all time high TTM FCF for Jounce Therapeutics?

Jounce Therapeutics all-time high TTM free cash flow is $190.31 M

What is Jounce Therapeutics TTM FCF year-on-year change?

Over the past year, JNCE TTM free cash flow has changed by +$54.07 M (+64.47%)